223Ra使用过程中的辐射安全评估

²²³Ra（氯化镭²²³Ra]注射液，多菲戈^®）是全球首个α粒子靶向治疗药物，用于治疗伴症状性骨转移且无已知内脏转移的去势抵抗前列腺癌患者。本文综述了氯化镭²²³Ra]注射液使用过程中的辐射安全评估，包括医护人员操作²²³Ra过程中的辐射安全、患者注射²²³Ra后的辐射安全以及患者注射²²³Ra后对家庭成员和公众人员的辐射影响。医护人员手部每次注射接受的有效剂量约为41 μSv，²¹⁹Rn引起的有效剂量约为3.5 μSv；患者注射²²³Ra后骨内膜和红骨髓是吸收剂量最高的组织，α粒子引起的吸收剂量分别为7.5×10^?7 Gy/Bq和7.2×10^?8 Gy/Bq；完成药物注射时，直接接触患者的平均辐射剂量率小于2 μSv h^?1 MBq^?1，距患者1 m处的平均辐射剂量率约为0.02 μSv h^?1 MBq^?1。患者注射药物后无需因放射性在医院特殊停留。

Safety evaluation of radiation during223Ra treatment

Radium ²²³Ra] dichloride injection (²²³Ra, Xofigo^®) is the first targeted alpha therapy for the treatment of patients with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastases. This article reviews the safety evaluation of radiation during ²²³Ra treatment, including radiation safety during ²²³Ra procedures for medical staff, radiation safety after ²²³Ra injection for patients, and radiation impacts on patients’ family members and the public following ²²³Ra injection. The effective dose to the hands of medical staff during each injection was approximately 41 μSv, with an effective dose of ²¹⁹Rn being 3.5 μSv; after ²²³Ra injection, patients showed the highest absorbed radiation dose in the endosteum and red bone marrow among other tissues, with absorbed alpha doses of 7.5×10^-7 Gy/Bq and 7.2×10^?8 Gy/Bq, respectively; at the completion of agent injection, the mean radiation dose rates in regions with direct contact with the patients and regions at 1 meter from the patients were less than 2 μSv h^?1 MBq^?1and 0.02 μSv h^?1 MBq^?1, respectively. It is not necessary for the patients to stay in the hospital due to radiation after agent injection.